Lucassen, M. J. J.
ter Wee, M. M. http://orcid.org/0000-0003-3670-4256
den Uyl, D.
Konijn, N. P. C.
Nurmohamed, M. T. http://orcid.org/0000-0002-6274-1934
Voskuyl, A. E. http://orcid.org/0000-0002-9699-1827
van Schaardenburg, D. http://orcid.org/0000-0003-4006-3762
Kerstens, P. J. S. M.
Bultink, I. E. M. http://orcid.org/0000-0002-5441-3420
Boers, M. http://orcid.org/0000-0002-6969-283X
Lems, W. F. http://orcid.org/0000-0002-6885-3953
Funding for this research was provided by:
Dutch Top Institute group
Pfizer Pharmaceuticals (WS905749)
Article History
Received: 8 May 2020
Accepted: 4 December 2020
First Online: 19 January 2021
Compliance with ethical standards
:
: Mike Nurmohamed has received speaker fees and advisory board fees from Janssen, Roche, Merck Sharp & Dohme, Pfizer, Eli Lilly, Bristol-Myers Squibb and Abbvie. Irene Bultink has received speaker fees or advisory board fees from Lilly Netherlands, Merck Sharp & Dohme, Amgen, UCB, Roche Netherlands, and Sanofi Genzyme. Maarten Boers has received consultancy fees from Pfizer, UCB and Teva. Willem Lems has received speaker fees and advisory boards from Eli Lilly, Amgen, Pfizer, UCB, Abbvie and Roche and an educational grant from Pfizer.All other authors have declared no conflicts of interest.
: Medical Ethics Committees at each participating centre approved the protocol; patients gave written informed consent before inclusion, and the study was conducted in accordance with the Declaration of Helsinki/Good Clinical Practice.